Intelligent Bio Solutions Inc. (INBS) Discusses FDA 510(k) Submission and Progress of Intelligent Fingerprinting Drug Screening System TranscriptSeeking Alpha · Sep 24, 2026
Intelligent Bio Solutions to Host Virtual Fireside Chat on September 24th at 4:30 p.m. ETGlobeNewsWire · Sep 10, 2026
Intelligent Bio Solutions Submits FDA 510(k) Package for Intelligent Fingerprinting Drug Screening System, Seeking U.S. Market ClearanceGlobeNewsWire · Sep 9, 2026
Intelligent Bio Solutions Achieves Above 98% Accuracy in Method Comparison Study, Supporting Planned 2026 FDA 510(k) SubmissionGlobeNewsWire · Sep 1, 2026
Intelligent Bio Solutions Announces Private Placement of up to $15 Million to a Single Existing Institutional Investor Priced At-the-Market Under Nasdaq RulesGlobeNewsWire · Sep 1, 2026
BlackRock Inc. Invests $149.96 Million in Intelligent Bio Solutions Inc. $INBSDefense World · Aug 29, 2026Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 19, 2026 | -$1.58 | -$1.34 | Beat |
| May 12, 2026 | $1.40 | -$1.80 | Miss |
| Feb 12, 2026 | $0.40 | -$2.82 | Miss |
| Nov 13, 2025 | -$1.50 | -$3.50 | Miss |
| Aug 15, 2025 | -$1.20 | -$3.60 | Miss |
| May 14, 2025 | -$2.80 | -$4.40 | Miss |